[an error occurred while processing this directive]
International Journal of Infectious Diseases: Volume 1, Number 3
Live Attenuated Varicella Vaccine
Anne A. Gershon, MD

Int J Infect Dis 1997; 1(3):130-134.

A history of the development of live attenuated varicella vaccine and its current use is presented. The vaccine is highly protective against severe varicella in all populations that have been studied. Vaccination of a healthy varicella-susceptible population is safe. Rarely the vaccine virus may be transmitted to varicella-susceptible contacts, resulting in an attenuated illness. Clinical reversion of vaccine virus to virulence has not been observed. Immunologically, adults do not respond as robustly as children to the vaccine; therefore two doses are recommended for individuals over 13 years of age, given 1 to 2 months apart. The epidemiology of zoster, which currently affects about 15% of the population, may also change with widespread vaccine use. In leukemic children, the incidence of zoster is reduced following immunization. It is predicted that zoster may also be less prevalent in healthy vaccinated persons; however, it will take a number of years before this can be demonstrated. Live attenuated varicella vaccine is now licensed for routine use to prevent varicella in many countries in Asia, in the United States, and in certain European countries.

Key Words: vaccine, varicella vaccine, varicella-zoster virus, zoster

Back to Table of Contents

The International Journal of Infectious Diseases is owned by
the International Society for Infectious Diseases.
The Journal is published quarterly for the ISID by B.C. Decker Inc.